CMOTEC B — Scandinavian ChemoTech AB Income Statement
0.000.00%
- SEK53.81m
- SEK52.16m
- SEK2.82m
Annual income statement for Scandinavian ChemoTech AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | SAS | — | — | — | SAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.556 | 0.131 | 0.049 | 0.473 | 2.82 |
Cost of Revenue | |||||
Gross Profit | 4.43 | 1.27 | 2.86 | -0.055 | 1.66 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 12.5 | 11 | 17.1 | 21.4 | 23.1 |
Operating Profit | -12 | -10.8 | -17.1 | -20.9 | -20.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -12.3 | -11.7 | -17.7 | -22.7 | -21.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -12.3 | -11.7 | -17.7 | -22.7 | -21.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -12.3 | -11.7 | -17.7 | -22.7 | -21.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -12.3 | -11.7 | -17.7 | -22.7 | -21.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.88 | -1.85 | -1.77 | -2.27 | -1.5 |
Dividends per Share |